Payment overview · 2025
General Payments
$853.13
36 reported records · 9 companies
Healthcare provider profile · identity verified
Sanjay Lodha, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1265595300
Verified facts
What the public records show
CMS Open Payments records show Sanjay Lodha, MD received $853.13 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $416.05 | 48.8% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.96 | 17.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.98 | 14.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.93 | 7.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.63 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.48 | 2.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.22 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.66 | 1.9% | 1 | 2025 |
| Bavarian Nordic A/S | Unresolved — no canonical attribution shown | $15.22 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $853.13 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $307.88 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.96 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $149.96 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.92 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.93 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.93 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| Vivotif Normalized: vivotif |
Drug | Bavarian Nordic A/S | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 174 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
174 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 693 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 678 | 139 |
| Famotidine | Famotidine | 581 | 111 |
| Losartan Potassium | Losartan Potassium | 535 | 131 |
| Metformin Hcl | Metformin Hcl | 453 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 67 |
| Simvastatin | Simvastatin | 387 | 89 |
| Furosemide | Furosemide | 335 | 45 |
| Eliquis | Apixaban | 321 | 24 |
| Montelukast Sodium | Montelukast Sodium | 283 | 110 |
| Gabapentin | Gabapentin | 266 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 41 |
| Jardiance | Empagliflozin | 203 | 31 |
| Clozapine | Clozapine | 201 | suppressed |
| Lisinopril | Lisinopril | 181 | 23 |
| Farxiga | Dapagliflozin Propanediol | 174 | 19 |
| Mirtazapine | Mirtazapine | 173 | 24 |
| Potassium Chloride | Potassium Chloride | 155 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 47 |
| Allopurinol | Allopurinol | 126 | 22 |
| Divalproex Sodium | Divalproex Sodium | 122 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 20 |
| Xarelto | Rivaroxaban | 119 | suppressed |
| Latanoprost | Latanoprost | 114 | 17 |
| Azithromycin | Azithromycin | 113 | 83 |
| Donepezil Hcl | Donepezil Hcl | 109 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 40 |
| Baclofen | Baclofen | 101 | 13 |
| Memantine Hcl | Memantine Hcl | 97 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 16 |
| Levetiracetam | Levetiracetam | 96 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 11 |
| Carvedilol | Carvedilol | 90 | 19 |
| Lactulose | Lactulose | 80 | 18 |
| Alendronate Sodium | Alendronate Sodium | 79 | 28 |
| Glipizide | Glipizide | 78 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 73 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 73 | 15 |
| Risperidone | Risperidone | 73 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 35 |
| Omeprazole | Omeprazole | 68 | 20 |
| Spironolactone | Spironolactone | 67 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 65 | 64 |
| Silver Sulfadiazine | Silver Sulfadiazine | 65 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 29 |
| Valsartan | Valsartan | 62 | 14 |
| Atenolol | Atenolol | 60 | 14 |
| Enalapril Maleate | Enalapril Maleate | 59 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 58 | suppressed |
| Olanzapine | Olanzapine | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 21 |
| Labetalol Hcl | Labetalol Hcl | 52 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 51 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Glipizide Er | Glipizide | 49 | 13 |
| Finasteride | Finasteride | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 11 |
| Santyl | Collagenase Clostridium Hist. | 43 | 12 |
| Prednisone | Prednisone | 42 | 14 |
| Sodium Chloride | Sodium Chloride 0.45 % | 40 | 21 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 23 |
| Nystatin | Nystatin | 35 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 17 |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Methimazole | Methimazole | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Corlanor | Ivabradine Hcl | 26 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Silodosin | Silodosin | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 19 |
| Ramipril | Ramipril | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 13 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Naproxen | Naproxen | 19 | 12 |
| Retacrit | Epoetin Alfa-Epbx | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 15 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | 13 |
| Anastrozole | Anastrozole | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Verquvo | Vericiguat | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $853.13 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, FARXIGA, GVOKE HYPOPEN, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, VOQUEZNA, Vivotif, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error